Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
Study Details
Study Description
Brief Summary
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
This study is a randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI. Children and adults diagnosed with MPS I, II or VI, with significant joint restrictions and pain will be randomized to adalimumab treatment or placebo treatment for the first 16 weeks. This will be followed by a 32-week open label adalimumab treatment phase.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Adalimumab 20 mg subQ every other week (weight 15to <30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing. |
Drug: Adalimumab Injection [Humira]
Investigational Drug
|
| Placebo Comparator: Placebo Saline placebo comparator |
Drug: Saline Solution for Injection
Placebo Comparator
|
| Experimental: Open-label adalimumab Open-label extension of adalimumab dose |
Drug: Adalimumab Injection [Humira]
Investigational Drug
|
Outcome Measures
Primary Outcome Measures
- Pain - 16 weeks [16 weeks]
Mean difference in bodily pain measured by the Children's Health Questionnaire - Parent Form 50 (CHQ-PF50) or the Medical Outcomes Study - Short Form 36 (SF-36) in treatment versus placebo at 16 weeks
- Adalimumab trough [32 weeks]
Percentage of subjects who achieve a goal trough concentration of adalimumab with every other week dosing
Secondary Outcome Measures
- Joint range-of-motion - 16 weeks [16 weeks]
Percentage of subjects who achieve a 5 degree or more improvement in joint range-ot-motion in treatment versus placebo at 16 weeks.
- Pain - 52 weeks [52 weeks]
Mean difference in bodily pain measured by the CHQ-PF50 or the SF-36 at 52 weeks compared to baseline.
- Joint range-of-motion - 52 weeks [52 weeks]
Percentage of subjects who achieve a 5 degree or more improvement in joint range-ot-motion at 52 weeks compared to baseline.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability [52 weeks]
Percentage of subjects who develop an AE and/or SAE
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female ≥5 years of age;
-
Diagnosis of MPS I, II or VI;
-
Treatment with ERT for ≥1 year or no treatment with ERT for ≥1 year;
-
Weight ≥15 kg;
-
Significant bodily pain reported by the CHQ-PF50 or SF-36 (> 1 SD more severe [below] than the general population mean);
-
≥ 3 joints with limitations in motion; and Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided.
Exclusion Criteria:
-
History of HCT less than 2 years prior to enrollment;
-
Immune suppression therapy less than 1 year prior to enrollment;
-
Active graft versus host disease;
-
Current diagnosis or history of lymphoma or other malignancy;
-
Current active infection;
-
History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria]; tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);
-
Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB
-
Congestive heart failure defined by an ejection fracture <50% measured by ECHO;
-
Demyelinating disorders (e.g., central nervous system [CNS] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome);
-
Hematologic abnormalities (e.g., pancytopenia, aplastic anemia);
-
Hepatitis B infection (active or chronic carrier);
-
Latex sensitivity;
-
Pregnancy or breastfeeding;
-
Known or suspected allergy to adalimumab or related products;
-
Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment;
-
Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or
-
Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Lundquist Institute at Harbor-UCLA Medical Center | Torrance | California | United States | 90502 |
Sponsors and Collaborators
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Investigators
- Principal Investigator: Lynda Polgreen, MD, The Lundquist Institute at Harbor-UCLA Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 31041-01